Patients with BRCA1- or BRCA2-linked ovarian cancers were shown to have a longer disease-free interval following chemotherapy and improved survival compared to patients with sporadic ovarian cancer ovarian cancer [35, 37, 38]. The gene discussed is BRCA1; the disease is ovarian cancer.